DNA Cell Cycle Analysis - Ploidy and S-Phase

ARUP LABORATORIES

Patient: [redacted]
DOB: [redacted] Age: 70 Sex: [redacted]
Patient Identifiers: [redacted]
Visit Number (FIN): [redacted]

Client: [redacted]

Physician: [redacted]

ARUP Test Code: 0095155

Collection Date: 03/14/2022
Received in lab: 03/19/2022
Completion Date: 03/24/2022

Patient Name: [redacted] Age: 70 Sex: [redacted] Sample [redacted]
Specimen Source and Type: COLON
Laboratory Accession Number: 22-078-400663



File analyzed: [redacted]
Date analyzed: 24-Mar-2022
Model: 1DA0n_DSD
Analysis type: Automatic analysis
Auto Linearity: No

Ploidy Mode: First cycle is diploid

Diploid: 100.00 %
Dip G1: 91.20 % at 51.66
Dip G2: 4.91 % at 103.31
Dip S: 3.90 % G2/G1: 2.00
%CV: 5.07

Total S-Phase: 3.90 %
Total B.A.D.: 39.65 %

Debris: 29.17 %
Aggregates: 31.63 %
Modeled events: 15048
All cycle events: 5898
Cycle events per channel: 112
RCS: 2.261

Interpretation: Diploid

Prognostic Data: As described in a recent review [Nat Rev Clin Oncol, 2016, 13(5):291-304], three large scale DNA-Cytometry studies performed with multivariate analyses have demonstrated an independent prognostic benefit of DNA aneuploidy in defined cohorts of patients with M0 colorectal cancer, in particular, stage II [Br J Cancer, 2014, 110(8):2159-64; Am J Gastro, 2013, 108(11):1785-93; Gastroent, 2006, 131(3):729-37]. Multivariate analyses indicate that tumor ploidy is an even stronger marker of prognosis than microsatellite instability in stage II colorectal cancer, with the presence of DNA aneuploidy being an independent indicator of a worse prognosis as measured by 5-year disease free survival.

ModFit LT V5.0.9(Win)

These results have been reviewed and approved by [redacted].

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Chart continues on following page(s)

Patient: [redacted] | **Date of Birth:** [redacted] | **Sex:** [redacted] | **Physician:** [redacted]
Patient Identifiers: [redacted] | **Visit Number (FIN):** [redacted]

Interpretive Data

INTERPRETIVE DATA: DNA Analysis - Ploidy and S-Phase
The diagnostic and prognostic importance of tumor DNA content depends on the tumor type and source of tissue. Interpretive information, if available for the tumor type, is included with the DNA histogram.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

END OF CHART